Literature DB >> 23069476

PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.

Erwan Guyot1, Angela Sutton, Pierre Rufat, Christelle Laguillier, Abdellah Mansouri, Richard Moreau, Nathalie Ganne-Carrié, Michel Beaugrand, Nathalie Charnaux, Jean-Claude Trinchet, Pierre Nahon.   

Abstract

BACKGROUND & AIMS: Several studies have reported an association between the genetic variant rs738409 (G) in the PNPLA3 gene and the risk of cirrhosis in various liver diseases. Our purpose was to assess the influence of this polymorphism on the risk of hepatocellular carcinoma (HCC) occurrence in two distinct longitudinal cohorts of patients with cirrhosis as well as its possible usefulness in HCC-risk model prediction.
METHODS: PNPLA3 rs738409 genotypes were assessed in 279 patients with alcoholic- and 253 patients with HCV-related cirrhosis. These patients were followed-up and screened for the risk of HCC, and the influence of rs738409 on the occurrence of liver cancer was assessed using the Kaplan-Meier method, then according to the multivariate Cox model.
RESULTS: In patients with HCV-related cirrhosis, rs738409 genotypes did not influence the risk of HCC development (log-rank = 0.7) or death (log-rank = 0.2). Conversely, in patients with alcoholic cirrhosis, the rs738409 (GG) genotype was an independent risk factor for HCC occurrence (HR = 1.72 [1.21-2.45], log-rank = 0.002) as well as older age, male gender, and higher BMI. Combining these features enabled HCC-risk stratification of this population into three groups with the 6-year cumulative incidence ranging from 3.4% (low risk, n = 58), 12.2% (intermediate risk, n = 163), and 51.7% (high risk, n = 58), respectively (HR = 4.3 [2.7-6.4]; log-rank <0.0001).
CONCLUSIONS: This study provides key data that affirm the influence of the rs738409 (GG) genotype on the occurrence of HCC in patients with alcoholic cirrhosis. Its combination with clinical features refines the selection of patients at higher risk of liver cancer development.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23069476     DOI: 10.1016/j.jhep.2012.09.036

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  43 in total

Review 1.  Nonalcoholic fatty liver disease in Asia: emerging perspectives.

Authors:  Wai-Kay Seto; Man-Fung Yuen
Journal:  J Gastroenterol       Date:  2016-09-16       Impact factor: 7.527

Review 2.  Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease.

Authors:  Nobuyuki Toshikuni; Mikihiro Tsutsumi; Tomiyasu Arisawa
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 3.  Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease.

Authors:  Pierre Nahon; Angela Sutton; Marianne Ziol; Jessica Zucman-Rossi; Jean-Claude Trinchet; Nathalie Ganne-Carrié
Journal:  Hepat Oncol       Date:  2015-01-12

Review 4.  The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis.

Authors:  Amit G Singal; Hema Manjunath; Adam C Yopp; Muhammad S Beg; Jorge A Marrero; Purva Gopal; Akbar K Waljee
Journal:  Am J Gastroenterol       Date:  2014-01-21       Impact factor: 10.864

Review 5.  Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.

Authors:  Paola Dongiovanni; Stefano Romeo; Luca Valenti
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 6.  Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.

Authors:  Tyler J Severson; Siddesh Besur; Herbert L Bonkovsky
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 7.  Systems biology for hepatologists.

Authors:  José M Mato; M Luz Martínez-Chantar; Shelly C Lu
Journal:  Hepatology       Date:  2014-06-18       Impact factor: 17.425

8.  Role of genetic polymorphisms in hepatitis C virus chronic infection.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Caterina Sagnelli; Lorenzo Onorato; Evangelista Sagnelli
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

Review 9.  PNPLA3 genetic variation in alcoholic steatosis and liver disease progression.

Authors:  Felix Stickel; Jochen Hampe; Eric Trépo; Christian Datz; Stefano Romeo
Journal:  Hepatobiliary Surg Nutr       Date:  2015-06       Impact factor: 7.293

Review 10.  Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes.

Authors:  Tracey G Simon; Adeel A Butt
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.